Boosting with adjuvanted SCB-2019 elicits superior Fcγ-receptor engagement driven by IgG3 to SARS-CoV-2 spike. (PubMed, NPJ Vaccines) - Jan 6, 2024 - "Individuals who were primed with 2 doses of the ChAdOx1 vaccine were equally divided into 4 groups and boosted with following formulations: Group 1: 9 μg SCB-2019 and Alhydrogel; Group 2: 9 μg SCB-2019, CpG 1018, and Alhydrogel; Group 3: 30 μg SCB-2019, CpG 1018, and Alhydrogel; Group 4: ChAdOx1. Moreover, from day 15 after vaccination, Group 3 exhibited higher IgG3 and FcγR binding across variants of concerns, including Omicron and its subvariants, compared to the ChAdOx1-boosted individuals. Overall, this highlights the potential of SCB-2019 as a cost-efficient boosting regimen effective across variants of concerns."
Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
|
|
Benjamin Kellman; Dansu Yuan; Eduardo Sprinz; Eveline Pipolo Milan; Galit Alter; Igor Smolenov; Isabela Garrido da Silva Gonzalez; José Cerbino Neto; Ralf Clemens; Ryan P McNamara; Sue Ann Costa Clemens; Wonyeong Jung
|